A Phase 4 interventional study of adalimumab and methotrexate in Rheumatoid Arthritis, sponsored by Abbott. Completed at 170 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-04-18.
Sponsored by Abbott · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 5th largest by enrollment, is one of 5 that started in 2006, is one of 33 in phase 4, and was the 16th registered.
3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Qilu Hospital of Shandong University · Sites in China
Ages 18–80
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 39 · Phase 4 33
First in 2000; this study’s year is marked. 5 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,032 is above the median of 96 across 2,223 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 160 across the 87 interventional studies. Of the 73 that completed or were terminated, 43 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 87 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
33 studies in Arthritis, Rheumatoid by Abbott: none open now, none under way, none of them phase 3. Of 30 finished, 19 (63%) have results posted.
Among the 33 studies in Arthritis, Rheumatoid by Abbott, this one is the 4th largest by enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2006, is one of 5 in phase 4, and was the 13th registered.
Abbott’s Arthritis, Rheumatoid studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Abbott’s 33 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study compared the safety and efficacy of combination therapy with adalimumab plus methotrexate (MTX) to that of MTX monotherapy (i.e., placebo plus MTX) in subjects with early rheumatoid arthritis (RA).
This was a 78-week, multicenter, randomized, double-blind, double-treatment period study designed to compare the safety and efficacy of adalimumab and MTX with placebo and MTX in subjects with early RA. Subjects were randomized to receive adalimumab 40 mg every other week (eow) or placebo subcutaneous injections in combination with orally administered MTX for 26 weeks (Period 1). All subjects in all arms received open-label MTX weekly throughout the study (both Period 1 and Period 2).
At Weeks 22 and 26, subjects were assessed for achievement of low disease activity, defined as a DAS28 score below 3.2. DAS28 is a measure of RA disease activity calculated using the number of tender and swollen joints (out of a total of 28), C-reactive protein level (CRP, a blood marker of inflammation), and the patient's global assessment of disease activity (indicated by marking a 10 cm line between very good and very bad). Subjects who achieved low disease activity at Week 22 and 26 in the adalimumab arm at the end of Period 1 were randomized to receive MTX monotherapy (placebo and MTX) or combination therapy (adalimumab and MTX) in a 1:1 ratio for the duration of Period 2 (52 weeks, i.e., to Week 78 of the study). Subjects achieving low disease activity at Week 22 and 26 in the placebo arm (MTX monotherapy) at the end of Period 1 continued to receive MTX monotherapy (and placebo injections in a blinded fashion) for the duration of Period 2. Subjects failing to achieve low disease activity at Week 22 and 26 at the end of Period 1 received open-label combination therapy during Period 2 regardless of treatment assignment in Period 1.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject must fulfill at least one of the following three criteria:
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2
Biological: adalimumab · Drug: methotrexate · Biological: placebo
Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2
Biological: adalimumab · Drug: methotrexate
Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA + MTX during Period 2
Biological: adalimumab · Drug: methotrexate
Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2
Drug: methotrexate · Biological: placebo
Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2.
Biological: adalimumab · Drug: methotrexate · Biological: placebo
Adalimumab 40 mg/0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)
Also known as: Humira, D2E7
Methotrexate 2.5 mg tablets administered orally once a week starting at 7.5 mg/week with dose escalation (weekly or every other week) by 2.5 mg intervals to 20 mg/week.
Placebo for adalimumab 0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)
Number of Subjects With Low Disease Activity (DAS28 Less Than 3.2) and No Radiographic Progression From Baseline (Change in mTSS Less Than or Equal to 0.5) at Week 78, Arm 2 vs. Arm 4
The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07, with scores below 3.2 indicating low disease activity. For the modified Total Sharp score (mTSS), x-rays of hand/wrist and feet joints are scored for erosions (0 to 5) and joint space narrowing (0 to 4). The erosion score and the narrowing score are added to determine the total score, which ranges from 0 (no damage) to 448.
Time frame: Week 78
Number of Subjects With Low Disease Activity (DAS28 Less Than 3.2) and No Radiographic Progression From Baseline (Change in mTSS Less Than or Equal to 0.5) at Week 78, Arm 2 vs. Arm 1
The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07, with scores below 3.2 indicating low disease activity. For the modified Total Sharp score (mTSS), x-rays of hand/wrist and feet joints are scored for erosions (0 to 5) and joint space narrowing (0 to 4). The erosion score and the narrowing score are added to determine the total score, which ranges from 0 (no damage) to 448.
Time frame: Week 78
Number of Subjects With DAS28 Low Disease Activity (DAS28 Less Than 3.2) at Week 78
The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07. A DAS28 less than 2.6 indicates clinical remission, DAS28 2.6 to 3.2 indicates low disease activity, DAS28 3.2 to less than 5.1 indicates moderate disease activity, and DAS28 of 5.1 or greater indicates high disease activity.
Time frame: Week 78
Number of Subjects With DAS28 Remission (DAS28 Less Than 2.6) at Week 78
The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07. A DAS28 less than 2.6 indicates clinical remission, DAS28 2.6 to 3.2 indicates low disease activity, DAS28 3.2 to less than 5.1 indicates moderate disease activity, and DAS28 of 5.1 or greater indicates high disease activity.
Time frame: Week 78
Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS Less Than or Equal to 0.5) at Week 78
For the modified Total Sharp score (mTSS), x-rays of hand/wrist and feet joints are scored for erosions (0 to 5) and joint space narrowing (0 to 4). The erosion score and the narrowing score are added to determine the total score, which ranges from 0 (no damage) to 448. An increase in mTSS from baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.
Time frame: Week 78
Number of Subjects Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 78
Subjects were responders if they had greater than or equal to 20% improvement in tender joint count; greater than or equal to 20% improvement in swollen joint count; and greater than or equal to 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant (C-reactive protein).
Time frame: Week 78
Number of Subjects Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 78
Subjects were responders if they had: greater than or equal to 50% improvement in tender joint count; greater than or equal to 50% improvement in swollen joint count; and greater than or equal to 50% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant (C-reactive protein).
Time frame: Week 78
Number of Subjects Meeting American College of Rheumatology 70% (ACR70) Response Criteria at Week 78
Subjects were responders if they had: greater than or equal to 70% improvement in tender joint count; greater than or equal to 70% improvement in swollen joint count; and greater than or equal to 70% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant (C-reactive protein).
Time frame: Week 78
Change From Baseline in DAS28 Score at Week 78
The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07. A DAS28 less than 2.6 indicates clinical remission, DAS28 2.6 to 3.2 indicates low disease activity, DAS28 3.2 to less than 5.1 indicates moderate disease activity, and DAS28 of 5.1 or greater indicates high disease activity.
Time frame: Baseline to Week 78
Number of Subjects With Clinical Disease Activity Index (CDAI) Low Disease Activity (CDAI Less Than or Equal to 10) at Week 78
The CDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, and physician's global assessment of disease activity. Scores range from 0 to 76.0, with a higher score reflecting worsening disease.
Time frame: Week 78
Number of Subjects With Simplified Disease Activity Index (SDAI) Low Disease Activity (SDAI Less Than or Equal to 11) at Week 78
The SDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, physician's global assessment of disease activity, and acute phase reactant (C-reactive protein). Scores range from 0.1 to 86.0, with a higher score reflecting worsening disease.
Time frame: Week 78
Number of Subjects With Clinical Disease Activity Index (CDAI) Remission (CDAI Less Than or Equal to 2.8) at Week 78
The CDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, and physician's global assessment of disease activity. Scores range from 0 to 76.0, with a higher score reflecting worsening disease.
Time frame: Week 78
Number of Subjects With Simplified Disease Activity Index (SDAI) Remission (SDAI Less Than or Equal to 3.3) at Week 78
The SDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, physician's global assessment of disease activity, and acute phase reactant (C-reactive protein). Scores range from 0.1 to 86.0, with a higher score reflecting worsening disease.
Time frame: Week 78
Change From Baseline in CDAI Score at Week 78
The CDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, and physician's global assessment of disease activity. Scores range from 0 to 76.0, with a higher score reflecting worsening disease.
Time frame: Baseline to Week 78
Change From Baseline in SDAI Score at Week 78
The SDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, physician's global assessment of disease activity, and acute phase reactant (C-reactive protein). Scores range from 0.1 to 86.0, with a higher score reflecting worsening disease.
Time frame: Baseline to Week 78
Change From Baseline in Synovitis Score According to the Rheumatoid Arthritis Magnetic Resonance Imaging (RA MRI) Scoring System (RAMRIS) at Week 78
Synovitis was assessed using high-field magnetic resonance imaging (MRI) of the hand and wrist. Images were read and scored according to the Outcomes Measures in Rheumatology Clinical Trials' Rheumatoid Arthritis MRI Scoring System (OMERACT RAMRIS). Synovitis in the wrist and finger joints in the most affected hand was scored from 0 (normal) to 3 (severe), for a maximum total score of 21.
Time frame: Baseline to Week 78
Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5) and Normal Function (HAQ-DI Less Than 0.5) at Week 78
In the Health Assessment Questionnaire Disability Index (HAQ-DI), participants rated their ability to perform daily tasks on a scale of 0 (without any difficulty) to 3 (unable to do). A mean score of 0-1 represents mild to moderate functional disability, 1-2 represents moderate to severe, 2-3 severe to very severe disability. For the modified Total Sharp score (mTSS), x-rays of hand/wrist and feet joints are scored for erosions (0 to 5) and joint space narrowing (0 to 4). The erosion score and the narrowing score are added to determine the total score, which ranges from 0 (no damage) to 448.
Time frame: Week 78
Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5), Normal Function (HAQ-DI Less Than or Equal to 0.5), and ACR70 Response at Week 78
In the Health Assessment Questionnaire Disability Index (HAQ-DI), a score of 0-1 represents mild to moderate, 1-2 moderate to severe, 2-3 severe to very severe disability. The modified Total Sharp score (mTSS) ranges from 0 (no joint damage) to 448 (worst joint damage). American College of Rheumatology 70% (ACR70) response indicates at least 70% improvement in tender and swollen joint counts and at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; HAQ-DI; and C-reactive protein.
Time frame: Week 78
Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5), Normal Function (HAQ-DI Less Than 0.5), and DAS28 Remission (DAS28 Less Than 2.6) at Week 78
In the Health Assessment Questionnaire Disability Index (HAQ-DI), a score of 0-1 represents mild to moderate, 1-2 moderate to severe, 2-3 severe to very severe disability. The modified Total Sharp score (mTSS) ranges from 0 (no joint damage) to 448 (severe joint damage). The Disease Activity Score (DAS28) ranges from 0.49 to 9.07, with scores less than 2.6 indicating clinical remission.
Time frame: Week 78
| Milestone | ADA+MTX | PBO+MTX | ADA+MTX/PBO+MTX (Arm 1) | ADA+MTX/ADA+MTX (Arm 2) | ADA+MTX/OL ADA+MTX (Arm 3) | PBO+MTX/PBO+MTX (Arm 4) | PBO+MTX/OL ADA+MTX (Arm 5) |
|---|---|---|---|---|---|---|---|
| Started | 515 | 517 | 0 | 0 | 0 | 0 | 0 |
| Completed | 466 | 460 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 49 | 57 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 19 | 15 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 7 | 12 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 8 | 6 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy/loss of efficacy | 1 | 6 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Subject moved/relocated | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Noncompliant with study drug | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Randomization error | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Suspected tuberculosis/positive test | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Study site closure | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Subject received new diagnosis | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Received wrong treatment/incorrect dose | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Failed to meet entry criteria | 8 | 7 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Took prohibited medication | 1 | 3 | 0 | 0 | 0 | 0 | 0 |
| Milestone | ADA+MTX | PBO+MTX | ADA+MTX/PBO+MTX (Arm 1) | ADA+MTX/ADA+MTX (Arm 2) | ADA+MTX/OL ADA+MTX (Arm 3) | PBO+MTX/PBO+MTX (Arm 4) | PBO+MTX/OL ADA+MTX (Arm 5) |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 102 | 105 | 259 | 112 | 348 |
| Completed | 0 | 0 | 89 | 95 | 216 | 97 | 295 |
| Not completed | 0 | 0 | 13 | 10 | 43 | 15 | 53 |
| Withdrew: Adverse event | 0 | 0 | 7 | 3 | 17 | 6 | 20 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 3 | 11 | 2 | 12 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 2 | 6 | 3 | 9 |
| Withdrew: Lack of efficacy/loss of efficacy | 0 | 0 | 2 | 1 | 6 | 2 | 6 |
| Withdrew: Received wrong treatment/incorrect dose | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Subject unable to find transportation | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Randomization error | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Noncompliant with study drug | 0 | 0 | 0 | 1 | 0 | 0 | 2 |
| Withdrew: Methotrexate intolerance | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Took prohibited medication | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07, with scores below 3.2 indicating low disease activity. For the modified Total Sharp score (mTSS), x-rays of hand/wrist and feet joints are scored for erosions (0 to 5) and joint space narrowing (0 to 4). The erosion score and the narrowing score are added to determine the total score, which ranges from 0 (no damage) to 448.
| Participants | ADA+MTX/PBO+MTX (Arm 1) | ADA+MTX/ADA+MTX (Arm 2) | ADA+MTX/OL ADA+MTX (Arm 3) | PBO+MTX/PBO+MTX (Arm 4) | PBO+MTX/OL ADA+MTX (Arm 5) |
|---|---|---|---|---|---|
| Number of Subjects With Low Disease Activity (DAS28 Less Than 3.2) and No Radiographic Progression From Baseline (Change in mTSS Less Than or Equal to 0.5) at Week 78, Arm 2 vs. Arm 4 | 59 | 73 | 94 | 61 | 129 |
The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07, with scores below 3.2 indicating low disease activity. For the modified Total Sharp score (mTSS), x-rays of hand/wrist and feet joints are scored for erosions (0 to 5) and joint space narrowing (0 to 4). The erosion score and the narrowing score are added to determine the total score, which ranges from 0 (no damage) to 448.
| Participants | ADA+MTX/PBO+MTX (Arm 1) | ADA+MTX/ADA+MTX (Arm 2) | ADA+MTX/OL ADA+MTX (Arm 3) | PBO+MTX/PBO+MTX (Arm 4) | PBO+MTX/OL ADA+MTX (Arm 5) |
|---|---|---|---|---|---|
| Number of Subjects With Low Disease Activity (DAS28 Less Than 3.2) and No Radiographic Progression From Baseline (Change in mTSS Less Than or Equal to 0.5) at Week 78, Arm 2 vs. Arm 1 | 59 | 73 | 94 | 61 | 129 |
The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07. A DAS28 less than 2.6 indicates clinical remission, DAS28 2.6 to 3.2 indicates low disease activity, DAS28 3.2 to less than 5.1 indicates moderate disease activity, and DAS28 of 5.1 or greater indicates high disease activity.
| Participants | ADA+MTX/PBO+MTX (Arm 1) | ADA+MTX/ADA+MTX (Arm 2) | ADA+MTX/OL ADA+MTX (Arm 3) | PBO+MTX/PBO+MTX (Arm 4) | PBO+MTX/OL ADA+MTX (Arm 5) |
|---|---|---|---|---|---|
| Number of Subjects With DAS28 Low Disease Activity (DAS28 Less Than 3.2) at Week 78 | 71 | 80 | 108 | 78 | 185 |
The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07. A DAS28 less than 2.6 indicates clinical remission, DAS28 2.6 to 3.2 indicates low disease activity, DAS28 3.2 to less than 5.1 indicates moderate disease activity, and DAS28 of 5.1 or greater indicates high disease activity.
| Participants | ADA+MTX/PBO+MTX (Arm 1) | ADA+MTX/ADA+MTX (Arm 2) | ADA+MTX/OL ADA+MTX (Arm 3) | PBO+MTX/PBO+MTX (Arm 4) | PBO+MTX/OL ADA+MTX (Arm 5) |
|---|---|---|---|---|---|
| Number of Subjects With DAS28 Remission (DAS28 Less Than 2.6) at Week 78 | 57 | 77 | 71 | 66 | 138 |
For the modified Total Sharp score (mTSS), x-rays of hand/wrist and feet joints are scored for erosions (0 to 5) and joint space narrowing (0 to 4). The erosion score and the narrowing score are added to determine the total score, which ranges from 0 (no damage) to 448. An increase in mTSS from baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.
| Participants | ADA+MTX/PBO+MTX (Arm 1) | ADA+MTX/ADA+MTX (Arm 2) | ADA+MTX/OL ADA+MTX (Arm 3) | PBO+MTX/PBO+MTX (Arm 4) | PBO+MTX/OL ADA+MTX (Arm 5) |
|---|---|---|---|---|---|
| Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS Less Than or Equal to 0.5) at Week 78 | 70 | 84 | 182 | 77 | 220 |
Subjects were responders if they had greater than or equal to 20% improvement in tender joint count; greater than or equal to 20% improvement in swollen joint count; and greater than or equal to 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant (C-reactive protein).
| Participants | ADA+MTX/PBO+MTX (Arm 1) | ADA+MTX/ADA+MTX (Arm 2) | ADA+MTX/OL ADA+MTX (Arm 3) | PBO+MTX/PBO+MTX (Arm 4) | PBO+MTX/OL ADA+MTX (Arm 5) |
|---|---|---|---|---|---|
| Number of Subjects Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 78 | 84 | 89 | 172 | 90 | 257 |
Subjects were responders if they had: greater than or equal to 50% improvement in tender joint count; greater than or equal to 50% improvement in swollen joint count; and greater than or equal to 50% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant (C-reactive protein).
| Participants | ADA+MTX/PBO+MTX (Arm 1) | ADA+MTX/ADA+MTX (Arm 2) | ADA+MTX/OL ADA+MTX (Arm 3) | PBO+MTX/PBO+MTX (Arm 4) | PBO+MTX/OL ADA+MTX (Arm 5) |
|---|---|---|---|---|---|
| Number of Subjects Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 78 | 72 | 82 | 120 | 78 | 198 |
Subjects were responders if they had: greater than or equal to 70% improvement in tender joint count; greater than or equal to 70% improvement in swollen joint count; and greater than or equal to 70% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant (C-reactive protein).
| Participants | ADA+MTX/PBO+MTX (Arm 1) | ADA+MTX/ADA+MTX (Arm 2) | ADA+MTX/OL ADA+MTX (Arm 3) | PBO+MTX/PBO+MTX (Arm 4) | PBO+MTX/OL ADA+MTX (Arm 5) |
|---|---|---|---|---|---|
| Number of Subjects Meeting American College of Rheumatology 70% (ACR70) Response Criteria at Week 78 | 57 | 73 | 78 | 64 | 137 |
The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07. A DAS28 less than 2.6 indicates clinical remission, DAS28 2.6 to 3.2 indicates low disease activity, DAS28 3.2 to less than 5.1 indicates moderate disease activity, and DAS28 of 5.1 or greater indicates high disease activity.
| Scores on a scale | ADA+MTX/PBO+MTX (Arm 1) | ADA+MTX/ADA+MTX (Arm 2) | ADA+MTX/OL ADA+MTX (Arm 3) | PBO+MTX/PBO+MTX (Arm 4) | PBO+MTX/OL ADA+MTX (Arm 5) |
|---|---|---|---|---|---|
| Change From Baseline in DAS28 Score at Week 78 | -3.54 ± 1.259 | -3.71 ± 1.134 | -2.70 ± 1.531 | -3.04 ± 1.513 | -3.07 ± 1.486 |
The CDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, and physician's global assessment of disease activity. Scores range from 0 to 76.0, with a higher score reflecting worsening disease.
| Participants | ADA+MTX/PBO+MTX (Arm 1) | ADA+MTX/ADA+MTX (Arm 2) | ADA+MTX/OL ADA+MTX (Arm 3) | PBO+MTX/PBO+MTX (Arm 4) | PBO+MTX/OL ADA+MTX (Arm 5) |
|---|---|---|---|---|---|
| Number of Subjects With Clinical Disease Activity Index (CDAI) Low Disease Activity (CDAI Less Than or Equal to 10) at Week 78 | 75 | 84 | 109 | 82 | 195 |
The SDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, physician's global assessment of disease activity, and acute phase reactant (C-reactive protein). Scores range from 0.1 to 86.0, with a higher score reflecting worsening disease.
| Participants | ADA+MTX/PBO+MTX (Arm 1) | ADA+MTX/ADA+MTX (Arm 2) | ADA+MTX/OL ADA+MTX (Arm 3) | PBO+MTX/PBO+MTX (Arm 4) | PBO+MTX/OL ADA+MTX (Arm 5) |
|---|---|---|---|---|---|
| Number of Subjects With Simplified Disease Activity Index (SDAI) Low Disease Activity (SDAI Less Than or Equal to 11) at Week 78 | 73 | 79 | 106 | 76 | 192 |
The CDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, and physician's global assessment of disease activity. Scores range from 0 to 76.0, with a higher score reflecting worsening disease.
| Participants | ADA+MTX/PBO+MTX (Arm 1) | ADA+MTX/ADA+MTX (Arm 2) | ADA+MTX/OL ADA+MTX (Arm 3) | PBO+MTX/PBO+MTX (Arm 4) | PBO+MTX/OL ADA+MTX (Arm 5) |
|---|---|---|---|---|---|
| Number of Subjects With Clinical Disease Activity Index (CDAI) Remission (CDAI Less Than or Equal to 2.8) at Week 78 | 47 | 58 | 39 | 54 | 94 |
The SDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, physician's global assessment of disease activity, and acute phase reactant (C-reactive protein). Scores range from 0.1 to 86.0, with a higher score reflecting worsening disease.
| Participants | ADA+MTX/PBO+MTX (Arm 1) | ADA+MTX/ADA+MTX (Arm 2) | ADA+MTX/OL ADA+MTX (Arm 3) | PBO+MTX/PBO+MTX (Arm 4) | PBO+MTX/OL ADA+MTX (Arm 5) |
|---|---|---|---|---|---|
| Number of Subjects With Simplified Disease Activity Index (SDAI) Remission (SDAI Less Than or Equal to 3.3) at Week 78 | 45 | 55 | 39 | 51 | 92 |
The CDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, and physician's global assessment of disease activity. Scores range from 0 to 76.0, with a higher score reflecting worsening disease.
| Scores on a scale | ADA+MTX/PBO+MTX (Arm 1) | ADA+MTX/ADA+MTX (Arm 2) | ADA+MTX/OL ADA+MTX (Arm 3) | PBO+MTX/PBO+MTX (Arm 4) | PBO+MTX/OL ADA+MTX (Arm 5) |
|---|---|---|---|---|---|
| Change From Baseline in CDAI Score at Week 78 | -33.30 ± 12.808 | -33.29 ± 12.964 | -29.06 ± 16.561 | -27.63 ± 15.526 | -31.30 ± 14.769 |
The SDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, physician's global assessment of disease activity, and acute phase reactant (C-reactive protein). Scores range from 0.1 to 86.0, with a higher score reflecting worsening disease.
| Scores on a scale | ADA+MTX/PBO+MTX (Arm 1) | ADA+MTX/ADA+MTX (Arm 2) | ADA+MTX/OL ADA+MTX (Arm 3) | PBO+MTX/PBO+MTX (Arm 4) | PBO+MTX/OL ADA+MTX (Arm 5) |
|---|---|---|---|---|---|
| Change From Baseline in SDAI Score at Week 78 | -35.61 ± 13.527 | -35.16 ± 13.784 | -31.00 ± 17.856 | -29.30 ± 17.120 | -33.43 ± 15.852 |
Synovitis was assessed using high-field magnetic resonance imaging (MRI) of the hand and wrist. Images were read and scored according to the Outcomes Measures in Rheumatology Clinical Trials' Rheumatoid Arthritis MRI Scoring System (OMERACT RAMRIS). Synovitis in the wrist and finger joints in the most affected hand was scored from 0 (normal) to 3 (severe), for a maximum total score of 21.
| Scores on a scale | ADA+MTX/PBO+MTX (Arm 1) | ADA+MTX/ADA+MTX (Arm 2) | ADA+MTX/OL ADA+MTX (Arm 3) | PBO+MTX/PBO+MTX (Arm 4) | PBO+MTX/OL ADA+MTX (Arm 5) |
|---|---|---|---|---|---|
| Change From Baseline in Synovitis Score According to the Rheumatoid Arthritis Magnetic Resonance Imaging (RA MRI) Scoring System (RAMRIS) at Week 78 | 2.00 ± 2.121 | -3.38 ± 2.562 | -3.25 ± 3.631 | -3.88 ± 3.351 | -4.27 ± 4.211 |
In the Health Assessment Questionnaire Disability Index (HAQ-DI), participants rated their ability to perform daily tasks on a scale of 0 (without any difficulty) to 3 (unable to do). A mean score of 0-1 represents mild to moderate functional disability, 1-2 represents moderate to severe, 2-3 severe to very severe disability. For the modified Total Sharp score (mTSS), x-rays of hand/wrist and feet joints are scored for erosions (0 to 5) and joint space narrowing (0 to 4). The erosion score and the narrowing score are added to determine the total score, which ranges from 0 (no damage) to 448.
| Participants | ADA+MTX/PBO+MTX (Arm 1) | ADA+MTX/ADA+MTX (Arm 2) | ADA+MTX/OL ADA+MTX (Arm 3) | PBO+MTX/PBO+MTX (Arm 4) | PBO+MTX/OL ADA+MTX (Arm 5) |
|---|---|---|---|---|---|
| Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5) and Normal Function (HAQ-DI Less Than 0.5) at Week 78 | 49 | 59 | 65 | 53 | 84 |
In the Health Assessment Questionnaire Disability Index (HAQ-DI), a score of 0-1 represents mild to moderate, 1-2 moderate to severe, 2-3 severe to very severe disability. The modified Total Sharp score (mTSS) ranges from 0 (no joint damage) to 448 (worst joint damage). American College of Rheumatology 70% (ACR70) response indicates at least 70% improvement in tender and swollen joint counts and at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; HAQ-DI; and C-reactive protein.
| Participants | ADA+MTX/PBO+MTX (Arm 1) | ADA+MTX/ADA+MTX (Arm 2) | ADA+MTX/OL ADA+MTX (Arm 3) | PBO+MTX/PBO+MTX (Arm 4) | PBO+MTX/OL ADA+MTX (Arm 5) |
|---|---|---|---|---|---|
| Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5), Normal Function (HAQ-DI Less Than or Equal to 0.5), and ACR70 Response at Week 78 | 37 | 56 | 40 | 43 | 67 |
In the Health Assessment Questionnaire Disability Index (HAQ-DI), a score of 0-1 represents mild to moderate, 1-2 moderate to severe, 2-3 severe to very severe disability. The modified Total Sharp score (mTSS) ranges from 0 (no joint damage) to 448 (severe joint damage). The Disease Activity Score (DAS28) ranges from 0.49 to 9.07, with scores less than 2.6 indicating clinical remission.
| Participants | ADA+MTX/PBO+MTX (Arm 1) | ADA+MTX/ADA+MTX (Arm 2) | ADA+MTX/OL ADA+MTX (Arm 3) | PBO+MTX/PBO+MTX (Arm 4) | PBO+MTX/OL ADA+MTX (Arm 5) |
|---|---|---|---|---|---|
| Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5), Normal Function (HAQ-DI Less Than 0.5), and DAS28 Remission (DAS28 Less Than 2.6) at Week 78 | 39 | 53 | 38 | 43 | 63 |
Collected over Adverse events reported during Period 1 (Weeks 0 to 26) are presented by Period 1 treatment group. Adverse events reported during Period 2 (Weeks 26 to 78) are presented by Period 2 treatment arm (Arm 1 through Arm 5).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ADA+MTX/PBO+MTX (Arm 1) | — | 11/102 (10.8%) | 28/102 (27.5%) |
| ADA+MTX/ADA+MTX (Arm 2) | — | 12/105 (11.4%) | 38/105 (36.2%) |
| ADA+MTX/OL ADA+MTX (Arm 3) | — | 18/259 (6.9%) | 106/259 (40.9%) |
| PBO+MTX/PBO+MTX (Arm 4) | — | 9/112 (8%) | 44/112 (39.3%) |
| PBO+MTX/OL ADA+MTX (Arm 5) | — | 32/348 (9.2%) | 134/348 (38.5%) |
| Period 1 ADA+MTX | — | 37/515 (7.2%) | 149/515 (28.9%) |
| Period 1 PBO+MTX | — | 32/517 (6.2%) | 128/517 (24.8%) |
| Event | ADA+MTX/PBO+MTX (Arm 1) | ADA+MTX/ADA+MTX (Arm 2) | ADA+MTX/OL ADA+MTX (Arm 3) | PBO+MTX/PBO+MTX (Arm 4) | PBO+MTX/OL ADA+MTX (Arm 5) | Period 1 ADA+MTX | Period 1 PBO+MTX |
|---|---|---|---|---|---|---|---|
| Benign prostatic hyperplasiaReproductive system and breast disorders | 0/102 | 2/105 | 0/259 | 0/112 | 0/348 | 0/515 | 0/517 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 0/102 | 0/105 | 1/259 | 0/112 | 4/348 | 1/515 | 2/517 |
| Benign mediastinal neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/102 | 0/105 | 0/259 | 0/112 | 0/348 | 0/515 | 0/517 |
| DizzinessNervous system disorders | 1/102 | 0/105 | 0/259 | 0/112 | 0/348 | 0/515 | 0/517 |
| GastroenteritisInfections and infestations | 1/102 | 0/105 | 0/259 | 0/112 | 0/348 | 0/515 | 0/517 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/102 | 0/105 | 0/259 | 0/112 | 0/348 | 0/515 | 1/517 |
| HeadacheNervous system disorders | 1/102 | 0/105 | 0/259 | 0/112 | 0/348 | 0/515 | 0/517 |
| Herpes zosterInfections and infestations | 1/102 | 0/105 | 0/259 | 0/112 | 0/348 | 1/515 | 0/517 |
| Kidney ruptureInjury, poisoning and procedural complications | 1/102 | 0/105 | 0/259 | 0/112 | 0/348 | 0/515 | 0/517 |
| Oesophageal squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/102 | 0/105 | 0/259 | 0/112 | 0/348 | 0/515 | 0/517 |
| Event | ADA+MTX/PBO+MTX (Arm 1) | ADA+MTX/ADA+MTX (Arm 2) | ADA+MTX/OL ADA+MTX (Arm 3) | PBO+MTX/PBO+MTX (Arm 4) | PBO+MTX/OL ADA+MTX (Arm 5) | Period 1 ADA+MTX | Period 1 PBO+MTX |
|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 7/102 | 4/105 | 15/259 | 9/112 | 27/348 | 60/515 | 55/517 |
| Upper respiratory tract infectionInfections and infestations | 5/102 | 5/105 | 29/259 | 7/112 | 27/348 | 35/515 | 38/517 |
| NasopharyngitisInfections and infestations | 5/102 | 6/105 | 23/259 | 4/112 | 23/348 | 34/515 | 25/517 |
| SinusitisInfections and infestations | 3/102 | 2/105 | 9/259 | 8/112 | 19/348 | 13/515 | 15/517 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/102 | 7/105 | 13/259 | 4/112 | 14/348 | 20/515 | 18/517 |
| Urinary tract infectionInfections and infestations | 2/102 | 5/105 | 12/259 | 5/112 | 22/348 | 25/515 | 22/517 |
| Alanine aminotransferase increasedInvestigations | 5/102 | 4/105 | 16/259 | 3/112 | 16/348 | 11/515 | 14/517 |
| InfluenzaInfections and infestations | 3/102 | 6/105 | 9/259 | 3/112 | 11/348 | 22/515 | 12/517 |
| BronchitisInfections and infestations | 3/102 | 2/105 | 14/259 | 6/112 | 19/348 | 16/515 | 20/517 |
| HypertensionVascular disorders | 1/102 | 5/105 | 6/259 | 6/112 | 7/348 | 18/515 | 19/517 |
| Age Categorical(participants) | ADA+MTX | PBO+MTX | ADA+MTX/PBO+MTX (Arm 1) | ADA+MTX/ADA+MTX (Arm 2) | ADA+MTX/OL ADA+MTX (Arm 3) | PBO+MTX/PBO+MTX (Arm 4) | PBO+MTX/OL ADA+MTX (Arm 5) | Total |
|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | — | — | — | — | — | 0 |
| Between 18 and 65 years | 418 | 431 | — | — | — | — | — | 849 |
| >=65 years | 97 | 86 | — | — | — | — | — | 183 |
| Age Continuous(years) | ADA+MTX | PBO+MTX | ADA+MTX/PBO+MTX (Arm 1) | ADA+MTX/ADA+MTX (Arm 2) | ADA+MTX/OL ADA+MTX (Arm 3) | PBO+MTX/PBO+MTX (Arm 4) | PBO+MTX/OL ADA+MTX (Arm 5) | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 50.7 ± 14.48 | 50.4 ± 13.62 | — | — | — | — | — | 50.6 ± 14.05 |
| Gender(participants) | ADA+MTX | PBO+MTX | ADA+MTX/PBO+MTX (Arm 1) | ADA+MTX/ADA+MTX (Arm 2) | ADA+MTX/OL ADA+MTX (Arm 3) | PBO+MTX/PBO+MTX (Arm 4) | PBO+MTX/OL ADA+MTX (Arm 5) | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 380 | 382 | — | — | — | — | — | 762 |
| Male | 135 | 135 | — | — | — | — | — | 270 |
| Region of Enrollment(participants) | ADA+MTX | PBO+MTX | ADA+MTX/PBO+MTX (Arm 1) | ADA+MTX/ADA+MTX (Arm 2) | ADA+MTX/OL ADA+MTX (Arm 3) | PBO+MTX/PBO+MTX (Arm 4) | PBO+MTX/OL ADA+MTX (Arm 5) | Total |
|---|---|---|---|---|---|---|---|---|
| Argentina | 32 | 29 | — | — | — | — | — | 61 |
| Australia | 5 | 8 | — | — | — | — | — | 13 |
| Austria | 11 | 12 | — | — | — | — | — | 23 |
| Belgium | 41 | 40 | — | — | — | — | — | 81 |
| Canada | 57 | 58 | — | — | — | — | — | 115 |
| Czech Republic | 22 | 19 | — | — | — | — | — | 41 |
| France | 4 | 8 | — | — | — | — | — | 12 |
| Germany | 43 | 41 | — | — | — | — | — | 84 |
| Hungary | 8 | 10 | — | — | — | — | — | 18 |
| Mexico | 26 | 27 | — | — | — | — | — | 53 |
| Netherlands | 0 | 3 | — | — | — | — | — | 3 |
| New Zealand | 3 | 3 | — | — | — | — | — | 6 |
| Norway | 4 | 5 | — | — | — | — | — | 9 |
| Poland | 12 | 9 | — | — | — | — | — | 21 |
| Slovakia | 6 | 3 | — | — | — | — | — | 9 |
| South Africa | 31 | 32 | — | — | — | — | — | 63 |
| Spain | 25 | 30 | — | — | — | — | — | 55 |
| Sweden | 10 | 11 | — | — | — | — | — | 21 |
| United Kingdom | 26 | 17 | — | — | — | — | — | 43 |
| United States | 149 | 152 | — | — | — | — | — | 301 |
Showing the first 100 of 170 sites across 21 countries. Choose a country and city above to see the rest.
The record gives a start of Dec 2006, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2011, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab